Promise of urinary nerve growth factor for assessment of overactive bladder syndrome

LUTS: Lower Urinary Tract Symptoms

Volumn 3, Issue 1, 2011, Pages 2-9

  Kuo, Hann Chorng ^a   Liu, Hsin Tzu ^a   Guan, Zhonghong ^b   Tyagi, Pradeep ^c   Chancellor, Michael B ^c  

^a TZU CHI UNIVERSITY   (Taiwan)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

^c OAKLAND UNIVERSITY WILLIAM BEAUMONT SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarker; Interstitial cystitis; Nerve growth factor; Overactive bladder; Urinary incontinence

Indexed keywords

BOTULINUM TOXIN A; MUSCARINIC RECEPTOR BLOCKING AGENT; NERVE GROWTH FACTOR; TOLTERODINE;

BLADDER DISEASE; DETRUSOR DYSSYNERGIA; DIAGNOSTIC VALUE; DISEASE COURSE; DISEASE SEVERITY; HUMAN; INTERSTITIAL CYSTITIS; NON INVASIVE MEASUREMENT; NONHUMAN; OVERACTIVE BLADDER; PAINFUL BLADDER SYNDROME; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; REVIEW; URINARY TRACT DISEASE; URODYNAMICS; UROTHELIAL DYSFUNCTION;

EID: 79954587722     PISSN: 17575664     EISSN: 17575672     Source Type: Journal    
DOI: 10.1111/j.1757-5672.2011.00087.x     Document Type: Review

References (59)

1. Abrams P, Kelleher CJ, Kerr LA, Rogers RG. Overactive bladder significantly affects quality of life. Am J Manag Care 2000; 6(Suppl 11): S580-90.
2. Stewart WF, Van Rooyen JB, Cundiff GW et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003; 20: 327-36.
3. Moorthy P, Lapitan MC, Quek PL et al. Prevalence of overactive bladder in Asian men: an epidemiological survey. BJU Int 2004; 93: 528-31.
4. Nixon A, Colman S, Sabounjian L et al. Validated patient reported measure of urinary urgency severity in overactive bladder for use in clinical trials. J Urol 2005; 174: 604-7.
5. Homma Y, Yoshida M, Seki N et al. Symptom assessment tool for overactive bladder syndrome: Overactive bladder symptom score. Urology 2006; 68: 318-23.
6. Hashim H, Abrams P. Is the bladder a reliable witness for predicting detrusor overactivity? J Urol 2006; 175: 191-5.
7. Malone-Lee JG, Al-Buheissi A. Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study. BJU Int 2009; 103: 931-7.
8. Chung SD, Liao CH, Kuo HC. Urgency severity scale could predict urodynamic detrusor overactivity in patients with overactive bladder syndrome. Neurourol Urodyn 2011 (in press).
9. Tanner R, Chambers P, Khadra MH, Gillespie JI. The production of nerve growth factor by human bladder smooth muscle cells in vivo and in vitro. BJU Int 2000; 85: 1115-9.
10. Clemow DB, Steers WD, Tuttle JB. Stretch-activated signaling of nerve growth factor secretion in bladder and vascular smooth muscle cells from hypertensive and hyperactive rats. J Cell Physiol 2000; 183: 289-300.
11. Zvara P, Vizzard MA. Exogenous overexpression of nerve growth factor in the urinary bladder produces bladder overactivity and altered micturition circuitry in the lumbosacral spinal cord. BMC Physiol 2007; 7: 9.
12. Lowe EM, Anand P, Terenghi G, Williams-Chestnut RE, Sinicropi DV, Osborne JL. Increased nerve growth factor levels in the urinary bladder of women with idiopathic sensory urgency and interstitial cystitis. Br J Urol 1997; 79: 572-7.
13. Vizzard MA. Changes in urinary bladder neurotrophic factor mRNA and NGF protein following urinary bladder dysfunction. Exp Neurol 2000; 161: 273-84.
14. Chuang YC, Fraser MO, Yu Y, Chancellor MB, de Groat WC, Yoshimura N. The role of bladder afferent pathways in bladder hyperactivity induced by the intravesical administration of nerve growth factor. J Urol 2001; 165: 975-9.
15. Seki S, Sasaki K, Fraser MO et al. Immunoneutralization of nerve growth factor in lumbosacral spinal cord reduces bladder hyperreflexia in spinal cord injured rats. J Urol 2002; 168: 2269-74.
16. Seki S, Sasaki K, Igawa Y et al. Suppression of detrusor-sphincter dyssynergia by immunoneutralization of nerve growth factor in lumbosacral spinal cord in spinal cord injured rats. J Urol 2004; 171: 478-82.
17. Birder LA, Wolf-Johnston A, Griffiths D, Resnick NM. Role of urothelial nerve growth factor in human bladder function. Neurourol Urodyn 2007; 26: 405-9.
18. Eryildirim B, Tarhan F, Gul AE, Erbay E, Kuyumcuoglu U. Immunohistochemical analysis of low-affinity nerve growth factor receptor in the human urinary bladder. Urol Int 2006; 77: 76-80.
19. Giannantoni A, Di Stasi SM, Nardicchi V et al. Botulinum-A toxin injections into the detrusor muscle decrease nerve growth factor bladder tissue levels in patients with neurogenic detrusor overactivity. J Urol 2006; 175: 2341-4.
20. Liu HT, Liu AB, Chancellor MB, Kuo HC. Urinary nerve growth factor level is correlated with the severity of neurological impairment in patients with cerebrovascular accident. BJU Int 2009; 104: 1158-62.
21. Steers WD, Kolbeck S, Creedon D, Tuttle JB. Nerve growth factor in the urinary bladder of the adult regulates neuronal form and function. J Clin Invest 1991; 88: 1709-15.
22. Okragly AJ, Niles AL, Saban R et al. Elevated tryptase, nerve growth factor, neurotrophin-3 and glial cell line-derived neurotrophic factor levels in the urine of interstitial cystitis and bladder cancer patients. J Urol 1999; 161: 438-41.
23. Dupont MC, Spitsberegen JM, Kim KB, Tuttle JB, Steers WD. Histological and neurotrophic changes triggered by varying models of bladder inflammation. J Urol 2000; 166: 1111-8.
24. Steers WD, Tuttle JB. Mechanisms of diseases: The role of nerve growth factor in the pathophysiology of bladder disorders. Nature Clin Pract Urol 2006; 3: 101-10.
25. Lommatzsch M, Braun A, Mannsfeldt A et al. Abundant production of brain-derived neurotrophic factor by adult visceral epithelia. Implications for paracrine and target-derived Neurotrophic function. Am J Pathol 1999; 155: 1183-93.
26. Kim JC, Park EY. Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder. J Urol 2006; 175: 1773-6.
27. Yokoyama T, Kumon H, Nagai A. Correlation of urinary nerve growth factor level with pathogenesis of overactive bladder. Neurourol Urodyn 2008; 27: 417-20.
28. Apostolidis A, Popat R, Yiangou Y, Cockayne D, Ford AP, Davis JB. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol 2005; 174: 977-82.
29. Liu HT, Kuo HC. Urinary nerve growth factor level could be a potential biomarker for diagnosis of overactive bladder. J Urol 2008; 179: 2270-4.
30. Liu HT, Kuo HC. Urinary nerve growth factor levels are increased in patients with bladder outlet obstruction with overactive bladder symptoms and reduced after successful medical treatment. Urology 2008; 72: 104-8.
31. Liu HT, Kuo HC. Urinary nerve growth factor levels are elevated in patients with overactive bladder and do not significantly increase with bladder distention. Neurourol Urodynam 2009; 28: 78-81.
32. Liu HT, Tyagi P, Chancellor MB, Kuo HC. Urinary nerve growth factor level is increased in patients with interstitial cystitis/bladder pain syndrome and decreased in responders to treatment. BJU Int 2009; 104: 1476-81.
33. Kuo HC, Liu HT, Tyagi P, Chancellor MC. Urinary nerve growth factor levels in urinary tract diseases with or without frequency urgency syndrome. LUTS 2010; 2: 88-94.
34. Kuo HC, Liu HT, Chancellor MC. Urinary nerve growth factor is a better biomarker than detrusor wall thickness for the assessment of overactive bladder with incontinence. Neurourol Urodynam 2010; 29: 482-7.
35. Liu HT, Tyagi P, Chancellor MB, Kuo HC. Urinary nerve growth factor but not prostaglandin E2 increases in patients with interstitial cystitis/painful bladder syndrome and detrusor overactivity. BJU Int 2010; 106: 1681-5.
36. Digesu GA, Khullar V, Cardozo L, Salvatore S. Overactive bladder symptoms: do we need urodynamics? Neurourol Urodyn 2003; 22: 105-8.
37. Hyman MJ, Groutz A, Blaivas JG. Detrusor instability in men: correlation of lower urinary tract symptoms with urodynamic findings. J Urol 2001; 166: 550-3.
38. Furuta A, Kita M, Suzuki Y et al. Association of overactive bladder and stress urinary incontinence in rats with pudendal nerve ligation injury. Am J Physiol Regul Integr Comp Physiol 2008; 294: R1510-6.
39. Kim JC, Kim DB, Seo SI, Park YH, Hwang TK. Nerve growth factor and vanilloid receptor expression, and detrusor instability, after relieving bladder outlet obstruction in rats. BJU Int 2004; 94: 915-8.
40. Lee SR, Hong CH, Choi YD, Kim JH. Increased urinary nerve growth factor as a predictor of persistent detrusor overactivity after bladder outlet obstruction relief in a rat model. J Urol 2010; 183: 2440-4.
41. Schnegelsberg B, Sun TT, Cain G et al. Overexpression of NGF in mouse urothelium leads to neuronal hyperinnervation, pelvic sensitivity, and changes in urinary bladder function. Am J Physiol Regul Integr Comp Physiol 2010; 298: R534-47.
42. Liu HT, Chancellor MB, Kuo HC. Urinary nerve growth factor level could be a biomarker in the differential diagnosis of mixed urinary incontinence in women. BJU Int 2008; 102: 1440-4.
43. Liu HT, Chancellor MB, Kuo HC. Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection. Eur Urol 2009; 56: 700-6.
44. Steers WD. Pathophysiology of overactive bladder and urge urinary incontinence. Rev Urol 2002; 4: S7-18.
45. Yoshimura N. Bladder afferent pathway and spinal cord injury: possible mechanisms inducing hyperreflexia of the urinary bladder. Prog Neurobiol 1999; 57: 583-606.
46. Zvarova K, Murray E, Vizzard MA. Changes in galanin immunoreactivity in rat llumbosacral spinal cord and dorsal root ganglia after spinal cord injury. J Comp Neurol 2004; 475: 590-603.
47. Jacobs BL, Smaidone MC, Tyagi V et al. Increased nerve growth factor in neurogenic overactive bladder and interstitial cystitis. Can J Urol 2010; 17: 4989-94.
48. Yamauchi H, Akino H, Ito H, Aoki Y, Nomura T, Yokoyama O. Urinary prostaglandin E(2) was increased in patients with suprapontine brain diseases, and associated with overactive bladder syndrome. Urology 2010; 76: 1267.
49. Apostolidis A, Dasgupta P, Fowler CJ. Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol 2006; 49: 644-50.
50. Liu HT, Chancellor MB, Kuo HC. Decrease of urinary nerve growth factor levels after antimuscarinic therapy in patients with overactive bladder. BJU Int 2009; 103: 1668-72.
51. Smaldone MC, Vodovotz Y, Tyagi V et al. Multiplex analysis of urinary cytokine levels in rat model of cyclophosphamide-induced cystitis. Urology 2009; 73: 421-6.
52. Tyagi P, Barclay D, Zamora R et al. Urine cytokines suggest an inflammatory response in the overactive bladder: a pilot study. Int Urol Nephrol 2010; 42: 629-35.
53. Chung SD, Liu HT, Kuo HC. Elevation of serum C-reactive protein and urinary nerve growth factor levels in patients with overactive bladder and intersitital cystitis/bladder pain syndrome implies chronic inflammation in the urinary bladder. Neourourol Urodyn 2011 (In Press).
54. Liu HT, Kuo HC. Intravesical botulinum toxin A injections plus hydrodistension can reduce nerve growth factor production and control bladder pain in interstitial cystitis. Urology 2007; 70: 463-8.
55. Liu HT, Shie JH, Chancellor MC et al. Mast Cells Infiltration is Increased in the Bladder Tissue of Patients with Overactive Bladder Symptoms and Interstitial Cystitis/Painful Bladder Syndrome. 2010; ICS abstract.
56. Shie JH, Kuo HC. Increased cell apoptosis and defected E-cadherin expression of the urothelium were associated with inflammation in patients with interstitial cystitis/painful bladder syndrome. BJU Int 2011 (In Press).
57. Elbadawi A, Yalla SV, Resnick NM. Structural basis of geriatric voiding dysfunction. III. Detrusor overactivity. J Urol 1993; 150: 1668-80.
58. Elbadawi A, Yalla SV, Resnick NM. Structural basis of geriatric voiding dysfunction. IV Bladder outlet obstruction. J Urol 1993; 150: 1681-95.
59. Liu HT, Wang YS, Kuo HC. Nerve growth factor levels are increased in urine but not urothelium in patients with detrusor overactivity. Tzu Chi Med J 2010; 22: 165-70.